Full history for every metric is available with a Kvantra account
Kronos Bio, Inc. (KRON)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 6 | 10 | 9 |
| Operating profit | $m | -93 | -70 | |||||
| Net profit | $m | -15 | -64 | -149 | -129 | -113 | -86 | -64 |
| EPS reported | $ | -1.43 | -1.07 | |||||
| Operating cashflow per share | $ | -1.09 | -1.09 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.09 | -1.09 | |||||
| Free cash flow | $m | -65 | -54 | |||||
| Net debt | $m | -112 | -100 | |||||
| Book value equity | $m | 88 | 80 | |||||
| Book value per share | $ | 1.46 | 1.31 | |||||
| Number of shares | m | 60.07 | 60.81 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.65 | 0.67 | |||||
| P/S LTM | x | 5.79 | 5.84 | |||||
| P/FCF LTM | x | -0.87 | -0.99 | |||||
| EV/EBITDA LTM | x | 0.04 | 0.94 | |||||
| EV/Sales LTM | x | -0.26 | -5.01 | |||||
| Earnings Yield LTM | % | -150.84% | -162.84% | |||||
| FCF Yield | % | -114.67% | -101.35% | |||||
| Quality | ||||||||
| ROE | % | -98.29% | -69.80% | |||||
| ROIC | % | -82.58% | -82.58% | |||||
| Operating margin | % | -943.21% | -943.21% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -664.49% | -664.49% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +56.62% | +21.15% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.63 | -2.26 | |||||
| Net Debt/EBITDA | x | 0.97 | 0.97 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -197.00% | -185.89% | |||||
| Net debt/Equity | x | -1.28 | -1.25 | |||||
| Gross debt/equity | x | 0.28 | 0.30 | |||||
Company overview
Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity. The company's primary investigational drug, entospletinib (ENTO), is an orally administered, selective inhibitor of spleen tyrosine kinase (SYK), designed for patients with acute myeloid leukemia. A registrational Phase 3 clinical trial is slated to evaluate ENTO in combination with induction chemotherapy for acute myeloid leukemia patients who possess NPM1 mutations. Furthermore, Kronos Bio is progressing KB-0742, an orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor, which is currently undergoing Phase 1/2 clinical assessment for the treatment of MYC-amplified solid tumors. Established in 2017, the company maintains its headquarters in San Mateo, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kronos Bio, Inc. (KRON)
Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity. The company's primary investigational drug, entospletinib (ENTO), is an orally administered, selective inhibitor of spleen tyrosine kinase (SYK), designed for patients with acute myeloid leukemia. A registrational Phase 3 clinical trial is slated to evaluate ENTO in combination with induction chemotherapy for acute myeloid leukemia patients who possess NPM1 mutations. Furthermore, Kronos Bio is progressing KB-0742, an orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor, which is currently undergoing Phase 1/2 clinical assessment for the treatment of MYC-amplified solid tumors. Established in 2017, the company maintains its headquarters in San Mateo, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free